Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03248596

Acronym

ECMO PFA-100

Enrollment

Registered

2017-08-14

Start date

2016-02-29

Completion date

2016-07-31

Last updated

2017-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With ECMO

Keywords

Extracorporeal Membrane Oxygenation (ECMO), Primary hemostasis

Brief summary

The aim of the study is a better understanding of hemorrhagic events causes in patients with ECMO, prevent them and decrease the number of transfusion.

Detailed description

The most frequent complication during ECMO is hemorrhage especially as a curative anticoagulant treatment is necessary. The primary hemostasis is also affected with a von Willebrand disease and thrombopathy, well known but not studied by recent tests.The identification of primary haemostasis deficits with these tools would allow to supply them and decrease the morbi-mortality related to the transfusion.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient older than 18 years old * Patient with ECMO * Patient hospitalized in an intensive care unit at the University Hospital of Rennes

Exclusion criteria

* Known history for constitutional pathology of the primary haemostasis * Platelets \< 100000 / mm3 or hematocrit \< 28 % between H+12 and H+24

Design outcomes

Primary

Measure	Time frame
Evaluate primary hemostasis in patient with ECMO at University Hospital of Rennes	Day 5

Countries

France

Outcome results